Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A

Jiangsu Hualan New Pharmaceutical Material Co., Ltd. Class A

SSZSE:301093
43.74
CNY
-0.61
(-1.38%)
0.18EPS
334.03P/E
13.45BMarket Cap
Apr 26Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.27
2.54
2.69
2.62
4.56
2.57
2.73
2.71
2.91
3.09
Basic EPS, GAAP
0.45
0.5
0.56
0.48
1.2
0.41
0.52
0.23
0.28
0.19
Free Cash Flow per Basic Share
0.12
0.51
0.36
0.55
0.51
-0.35
-0.32
-0.07
-0.08
- -
Dividend per Share
0.25
0.09
0.31
0.3
0.02
0.42
0.18
0.36
0.12
0.05
Book Value per Share
1.32
1.82
2.11
2.32
10.62
10.62
10.83
10.46
10.27
10.35
Tangible Book Value per Share
1.2
1.7
1.98
2.2
10.52
10.52
10.57
10.07
9.88
9.97
Basic Weighted Avg Shares
171
171
171
171
180
228
228
216
213
207
Sales/Revenue/Turnover
388
434
460
446
821
584
623
586
619
638
Operating Margin (%)
26.95
25.64
51.78
23.54
31.8
12.61
13.8
6.92
9.28
6.72
Depreciation Expense
29
31
48
29
31
37
44
56
68
- -
Net Income, GAAP
77
86
95
81
216
94
118
50
60
39
Effective Tax Rate (%)
15.05
15.06
15
15.04
14.62
12.65
14.09
15.33
13.41
10.45
Profit Margin (%)
19.8
19.85
20.7
18.23
26.32
16.05
18.93
8.45
9.71
6.12
Working Capital
-39
60
106
141
2,076
1,935
1,801
1,522
1,520
1,263
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
83
62
Total Equity
225
311
360
396
2,416
2,416
2,486
2,249
2,197
2,208
Return on Invested Capital (%)
- -
21.28
22.09
17.13
14.62
3.99
4.86
2.2
2.72
- -
Return on Capital (%)
- -
33.18
29.35
18.17
14.78
3.87
4.83
2.1
2.72
- -
Return on Common Equity (%)
- -
32.15
28.36
21.5
15.36
3.88
4.81
2.1
2.71
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
18
69
69
LT Borrowings
65
65
62
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
213
213
213
Market Capitalization
13,658
22,239
13,451

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,650
1,690
1,555
Cash, Cash Equivalents & STI
1,183
1,226
1,076
Accounts Receivable, Net
180
214
184
Inventories
147
141
162
Total Current Liabilities
175
247
292
Payables & Accruals
- -
- -
- -
ST Debt
18
69
69
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
100.13%
-2.32%
Free Cash Flow
- -
-51.23%
16.7%
Net Income, GAAP
- -
19.63%
21.39%
Sales/Revenue/Turnover
- -
12.3%
5.63%
Total Cash Common Dividend
- -
379.93%
-66.27%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
127
157
139
164
586
2025
146
163
- -
178
619
2026
130
168
162
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.12
0.07
-0.01
0.23
2025
0.09
0.12
- -
0.03
0.28
2026
- -
0.03
0.12
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.36
2025
- -
- -
- -
- -
0.12
2026
- -
- -
0.05
- -
- -

Company Description

CEO
Yi Min Hua
Full Time Employees
945
Sector
Process industries
Industry
Containers/Packaging
Address
Jiangyin China
IPO Date
Nov 1, 2021
Website
hlnpm.com
Business
Jiangsu Hualan New Pharmaceutical Material Co., Ltd. is a China-based manufacturer and supplier specializing in the research, development, production, and commercialization of primary pharmaceutical packaging materials and medical elastomer components. Founded in 1992 and headquartered in Jiangyin, Jiangsu Province, the company provides direct-contact sealing solutions for injectable pharmaceuticals, biologics, and medical devices. Its product portfolio comprises film-coated chlorobutyl and bromobutyl rubber stoppers for lyophilized powder injections, biological preparations, and sensitive chemical drugs; standard halobutyl rubber stoppers for large-volume infusion solutions, small-volume parenterals, and antibiotic formulations; elastomeric plungers, tip caps, and needle shields for prefilled syringes and cartridge injection systems; rubber stoppers for vacuum blood collection tubes; aluminum-plastic combination caps and flip-off safety seals; and custom-engineered elastomeric sealing parts for medical apparatus. The company distributes its products to pharmaceutical corporations, biotechnology firms, contract development and manufacturing organizations, and clinical healthcare providers throughout China and across international markets in Europe, North America, Southeast Asia, and the Middle East. In recent operational and strategic developments, Jiangsu Hualan New Pharmaceutical Material Co., Ltd. has scaled its smart manufacturing capabilities by commissioning high-precision automated production facilities, expanding capacity for advanced fluoropolymer-laminated closures and prefillable syringe components to meet evolving biopharmaceutical packaging demands. The company has also deepened strategic supply partnerships with prominent domestic and multinational drug manufacturers, advanced international regulatory registrations under FDA and European pharmacopoeia standards, and expanded research and development initiatives focused on high-barrier elastomer materials and ultra-low particle packaging solutions.